Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation

Immune checkpoints, such as programmed death-ligand 1 (PD-L1), limit T-cell function and tumor cells use this ligand to escape the anti-tumor immune response. Treatments with monoclonal antibodies blocking these checkpoints have shown long-lasting responses, but only in a subset of patients. This st...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jessica Bridoux, Katrijn Broos, Quentin Lecocq, Pieterjan Debie, Charlotte Martin, Steven Ballet, Geert Raes, Sara Neyt, Christian Vanhove, Karine Breckpot, Nick Devoogdt, Vicky Caveliers, Marleen Keyaerts, Catarina Xavier
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2020-09-01
Colecção:	Biomolecules
Assuntos:	Nanobody PD-L1 site-specific PET gallium-68 Sortase A
Acesso em linha:	https://www.mdpi.com/2218-273X/10/10/1388
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!